1. Traceability in Healthcare II Vision June/July 2011

2. © 2008 GS1 GS1 Members Vision for Traceability in Healthcare 2 Full, End to End, actionable visibility of finished pharmaceuticals and medical devices in healthcare globally, from Point of Production 1 to Point of Use 2 All authentic items are identified with the appropriate GS1 Identification Keys (e.g. GTIN) and appropriate Application Identifier (AI, e.g. Serial No. AI(21)), if applicable, at point of production Supply chain identifiers are associated with the patient and remain with/on items throughout their intended useful life All physical locations are identified with the appropriate GS1 Identification Key (e.g. GLN) across the entire supply chain All patients and care givers, when in a care giving environment, are identified with the appropriate GS1 identification Keys Agreed master data is captured and shared (e.g. via GDSN) amongst trading partners Agreed transactional data is captured and shared (e.g. via business-to-business messaging) amongst trading partners Agreed event data is captured and shared (e.g. via EPCIS) amongst trusted traceability stakeholders, based on data sharing/security policies SO THAT: 1.The terms production or producer can also mean commercially available, manufacture(r), creation(or), compounding(er)… 2.The terms use or used can also mean consumed, infused, implanted, destroyed

3. © 2008 GS1 Full, End to End, actionable visibility of finished pharmaceuticals and medical devices in healthcare globally, from Point of Production 1 to Point of Use 2 SO THAT: Items can be tracked (forward / downstream) across the entire supply chain (production to use) in real time Items can be traced (backward / upstream) across the entire supply chain (from current location back to the producer) in real time Item identification is available for use at patient bedside to ensure the Patient Rights 3 are achievable Patients Electronic Health Records (EHRs) are updated with agreed traceability information, including Care Giver identification Counterfeit products are detected when entering the legitimate supply chain A product recall would be fast, efficient and effective 3 1.The terms production or producer can also mean commercially available, manufacture(r), creation(or), compounding(er)… 2.The terms use or used can also mean consumed, infused, implanted, destroyed 3.Pharmaceuticals (5): Right patient, right drug, right dose, right route, right time. Medical Devices (8): right device, right location, right time, right condition, right procedure, right anatomic site, right patient, right user GS1 Members Vision for Traceability in Healthcare

4. © 2008 GS1 Version Control VersionDateChange Implemented by: ChangeReason for Change 0.130 Jan 09Janice KiteN/A 0.221 Apr 09Janice KiteChange wording of penultimate bullet from: Counterfeit products cannot enter the legitimate supply chain without being immediately detected To: Counterfeit products are detected when entering the legitimate supply chain Increase clarity and more realistic 0.212 Jun 09Janice KiteMinor editorial corrections to MissionCorrections and clarity 0.222 Mar 10Janice KiteSeparate Vision on to 2 slides and add a bullet related to patient / care giver Identification Format and additional bullet 0.328 Apr 10Janice KiteAdded further clarity to some bullets – i.e. added Application Identifiers to first bullet To reflect the changes identified whilst developing the GS1 Healthcare Guidance on Traceability 0.319 May 10Janice KiteAdded further clarity and brevity to tag lineChanges to reflect discussions in the GS1 HC Public Policy sub-group developing Traceability White Paper 0.322 June 10Janice KiteReplaced all items with finished pharmaceuticals and medical devices to tag line Discussion at Healthcare Leadership Team meeting at GS1 HC Conference in Geneva, Switzerland. Draft7 Jun 11Janice KiteAdded bullet on transactional data; added trusted to indicate that visibility of data is/can be restricted Comments from CoC/CoO (NCeP) Work Group Draft21 Jun 11Janice KiteFurther textual amendmentsBased on feedback to previous draft from TH-II & NCeP Co- Chairs. In preparation for HC LT review/approval (28 Jun 2011)

5. Contact Details Janice Kite Traceability Director Healthcare GS1 Global Office Avenue Louise 326, bte 10 B-1050 Brussels, Belgium T + 44 118 944 1580 M +44 791 211 3191 E janice.kite@gs1.org W www.gs1.org